Table 1.
Demographics and baseline characteristics
| Characteristic | |
|---|---|
| Age, years | 59.0 (11.6) |
| Race, n (%) | |
| Asian | 8 (3.7) |
| Black or African American | 8 (3.7) |
| White | 194 (90.2) |
| Other | 5 (2.3) |
| Female, n (%) | 94 (43.7) |
| HbA1c, mmol/mol | 74.0 (18.3) |
| HbA1c, % | 8.9 (1.7) |
| HbA1c < 53.0 mmol/mol (7.0%), n (%) | 20 (9.3) |
| Fasting plasma glucose, mmol/La | 12.0 (4.9) |
| Body weight, kgb | 107.8 (24.4) |
| Body mass index, kg/m2c | 37.2 (7.95) |
| Waist circumference, cmd | 118.6 (16.3) |
| Diabetes duration, years | 11.0 (6.3) |
| eGFR, mL/min/1.73 m2e | 83.6 (21.2) |
| Comorbid conditions, n (%) | |
| Diabetic retinopathy | 60 (27.9) |
| Diabetic neuropathy | 25 (11.6) |
| Diabetic nephropathy | 21 (9.8) |
| Cardiovascular history, n (%) | |
| Hypertension | 144 (67.0) |
| Dyslipidaemia | 91 (42.3) |
| Coronary heart disease | 33 (15.3) |
| Heart failure | 9 (4.2) |
| Stroke | 6 (2.8) |
| Peripheral vascular disease | 5 (2.3) |
| Cardiovascular medications, n (%) | |
| Cardiac therapy | 9 (4.2) |
| Antihypertensive agents | 18 (8.4) |
| Diuretics | 35 (16.3) |
| Vasoprotective agents | 1 (0.5) |
| Beta-blocking agents | 50 (23.3) |
| Calcium channel blockers | 60 (27.9) |
| Agents acting on the renin–angiotensin system | 130 (60.5) |
| Lipid-modifying agents | 143 (66.5) |
| Platelet aggregation inhibitorsf | 39 (18.1) |
| Other antithrombotic agents | 10 (4.7) |
| Reasons to initiate semaglutide, n (%)g | |
| Improve glycaemic control | 192 (89.3) |
| Weight reduction | 155 (72.1) |
| Issues with hypoglycaemia | 9 (4.2) |
| Address cardiovascular risk factors | 42 (19.5) |
| Simplify current treatment regimen | 37 (17.2) |
| Convenience | 41 (19.1) |
| Other | 10 (4.7) |
| Starting dose of semaglutide, n (%) | |
| 0.25 mg | 204 (94.9) |
| 0.5 mg | 8 (3.7) |
| 1.0 mg | 3 (1.4) |
Values are based on FAS (n = 215) unless otherwise noted. Data on continuous variables are mean (standard deviation) unless otherwise specified
eGFR estimated glomerular filtration rate, FAS full analysis set, HbA1c glycated haemoglobin
an = 26
bn = 214
cn = 213
dn = 128
en = 193
fExcluding heparin
gMore than one reason for initiating semaglutide could be selected